ArticleMetabolites2025
Study on Stability of Remifentanil, Sufentanil, and Their Metabolites in Human Whole Blood and Urine.
Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe accurate detection of remifentanil and sufentanil in biological samples is challenged by their rapid metabolism and instability, complicating clinical and forensic toxicology analysis. This study aimed to evaluate the stability of remifentanil, sufentanil, and their primary metabolites-remifentanil acid and norsufentanil-in human whole blood and urine.
methodsA high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated for simultaneous quantification, demonstrating satisfactory linearity (0.10-200 ng/mL, r
resultsRemifentanil exhibited significant instability in whole blood, degrading over 50% within 6 h at 4 °C, whereas stability was markedly improved at -80 °C and in sodium citrate-containing samples. Remifentanil acid remained stable for up to 35 days at -80 °C. Sufentanil was generally more stable, particularly at -80 °C in both blood and urine, while norsufentanil remained stable for 7 days at -20 °C in citrate-anticoagulated blood but degraded rapidly at 4 °C. These findings support specific recommendations for sample preservation, including storage at -80 °C and the use of sodium citrate as an anticoagulant, to enhance detection reliability in toxicological and pharmacokinetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.